Stocks Health care TECH
NASDAQ · Health careBIO-TECHNE Corp (TECH)
BIO-TECHNE Corp brought in $1.2B of revenue over the twelve months to September 30, 2026, up 0.9% from a year earlier. Net income was $171.9M, a net margin of 14.0%. Operating cash flow minus capital spending left $263.2M of free cash flow in fiscal 2026. At September 30, 2026 it held $350M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about BIO-TECHNE Corp
- Net worth
- BIO-TECHNE Corp has a market value (market cap) of $11.4B at the latest share price, and shareholders' equity of $2.2B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $1.2B (-0.4% year on year), with net income of $181.8M. Over the 12 months to September 30, 2026: revenue $1.2B, net income $171.9M.
- Cash flow
- In fiscal 2026 operations brought in $292.1M of cash; after $28.9M of capital spending, free cash flow was $263.2M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- BIO-TECHNE Corp's next report was expected around November 4, 2026 and is not on file with the SEC yet.
- Dividend
- BIO-TECHNE Corp declared dividends of $0.32 per share in fiscal 2026, a yield of 0.44% at the current price.
What BIO-TECHNE Corp does
BIO-TECHNE Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TECH.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $1.2B | $181.8M | $1.16 | $263.2M |
| 2025 | $1.2B | $73.4M | $0.46 | $256.6M |
| 2024 | $1.2B | $168.1M | $1.05 | $236.1M |
| 2023 | $1.1B | $285.3M | $1.76 | $216.1M |
| 2022 | $1.1B | $272.1M | $1.66 | $280.4M |
| 2021 | $931M | $140.4M | $0.87 | $307.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TECH ranks in Health care
Dividends
BIO-TECHNE Corp declared $0.32 per share in fiscal 2026. At the current price that is a yield of 0.44%. It paid out $49.9M in cash dividends, 27% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2026 | $0.32 | $49.9M | 27% |
| 2025 | $0.32 | $50.4M | 69% |
| 2024 | $0.32 | $50.4M | 30% |
| 2023 | $0.32 | $50.3M | 18% |
| 2022 | $0.32 | $50.2M | 18% |
| 2021 | $0.32 | $49.6M | 35% |
Latest SEC filings
What BIO-TECHNE Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 4.6% to $299.7M versus the same quarter last year; diluted EPS $0.18 versus $0.24.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026Other event 8-K
- October 28, 2026Annual report (amended) 10-K/A · period to June 30, 2026Revenue was flat at $1.2B versus the prior year; diluted EPS $1.16 versus $0.46.
- September 23, 2026
- September 14, 2026Additional proxy material DEFA14A
- September 14, 2026Other event 8-K
- September 9, 2026Additional proxy material DEFA14A
- September 2, 2026Additional proxy material DEFA14A
- August 25, 2026Additional proxy material DEFA14A
What is TECH worth? A DCF from its reported cash flow
Insider trades
What the people running BIO-TECHNE Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 25 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 1, 2026 | Hippel JamesCFO | Exercised options | 11,545 | - |
| November 1, 2026 | Hippel JamesCFO | Shares withheld for tax | 5,096 | $370.3K |
| November 1, 2026 | Kelderman KimChief Executive Officer, Director | Shares withheld for tax | 2,385 | $173.3K |
| October 29, 2026 | Higgins John LDirector | Received as pay | 2,750 | - |
| October 29, 2026 | Keegan Joseph DDirector | Received as pay | 2,750 | - |
| October 29, 2026 | Herr Amy E.Director | Received as pay | 2,750 | - |
| October 29, 2026 | Klimovsky Judith V.Director | Received as pay | 2,750 | - |
| October 29, 2026 | Seth AlpnaDirector | Received as pay | 2,750 | - |
Who owns TECH
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 8.1% | August 6, 2026 |
| Vanguard Capital Management13G, passive | 7.38% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 596 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 14,025,816 | +1,761,303 |
| Fmr LLC | 12,794,784 | +4,894,856 |
| Vanguard Capital Management LLC | 10,218,558 | +38,849 |
| Goldman Sachs Group Inc | 7,343,324 | +5,399,790 |
| Hbk Investments L P | 6,825,000 | new |
| Vanguard Portfolio Management LLC | 6,506,360 | +26,023 |
| Morgan Stanley | 6,374,717 | -2,158,156 |
| State Street Corp | 5,980,370 | +111,974 |
| Geode Capital Management, LLC | 5,351,464 | +239,044 |
| Invesco Ltd. | 4,986,424 | +397,718 |
| Ruane, Cunniff & Goldfarb L.P. | 3,348,841 | -43,160 |
| Snyder Capital Management L P | 3,163,816 | +1,281,518 |
| Neuberger Berman Group LLC | 2,844,692 | -496,145 |
| Massachusetts Financial Services Co | 2,746,462 | -986,786 |
| Mairs & Power Inc | 2,700,698 | -49,584 |
| Capital Research Global Investors | 2,621,890 | -566,320 |
| UBS Group AG | 2,478,607 | -575,736 |
| Dimensional Fund Advisors LP | 2,253,512 | +280,376 |
| Whitebox Advisors LLC | 2,100,001 | new |
| Sumitomo Mitsui Trust Group, Inc. | 2,067,324 | +13,030 |
Insiders
13 insiders reported holding 510,080 shares in total, about $37.1M at the last price.
| Holder | Shares |
|---|---|
| Hippel JamesCFO | 176,720 |
| Kelderman KimChief Executive Officer, Director | 80,509 |
| Higgins John LDirector | 80,004 |
| Baumgartner Robert VDirector | 56,884 |
| Geist WilliamPRESIDENT, PROTEIN SCIENCES | 25,031 |
| Keegan Joseph DDirector | 18,161 |
| Seth AlpnaDirector | 18,161 |
| Vessey RupertDirector | 13,737 |
| Bohnen ShaneSVP - General Counsel | 10,407 |
| Crouse Steven C.President - Diag & Spatial Bi | 10,237 |
Questions about TECH
What does BIO-TECHNE Corp do?
BIO-TECHNE Corp is a company in the Health care sector, listed on NASDAQ as TECH. Its shares trade on NASDAQ under the ticker TECH.
What is BIO-TECHNE Corp's net worth?
BIO-TECHNE Corp has a market value (market cap) of $11.4B at the latest share price, and shareholders' equity of $2.2B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is BIO-TECHNE Corp profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $171.9M on revenue of $1.2B, a net margin of 14.0%.
How much revenue does BIO-TECHNE Corp make?
Over the twelve months to September 30, 2026 BIO-TECHNE Corp reported revenue of $1.2B. That is 0.9% more than a year earlier.
When did BIO-TECHNE Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is BIO-TECHNE Corp's next earnings report?
BIO-TECHNE Corp's next report was expected around November 4, 2026 and is not on file with the SEC yet.
Does BIO-TECHNE Corp pay a dividend?
Yes. BIO-TECHNE Corp declared dividends of $0.32 per share in fiscal 2026, a yield of 0.44% at the current price.
Similar companies
Compare TECH with
Follow TECH
Get an email when BIO-TECHNE Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values BIO-TECHNE Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.